안과 시장 : 질병별, 제품 유형별, 최종 사용자별 - 세계 예측(2025-2030년)

The Ophthalmology Market was valued at USD 59.78 billion in 2023, expected to reach USD 63.72 billion in 2024, and is projected to grow at a CAGR of 6.62%, to USD 93.69 billion by 2030.

Ophthalmology, the branch of medicine and surgery dedicated to the diagnosis and treatment of eye disorders, is witnessing a significant transformation driven by technological advancements and increasing prevalence of eye diseases. The market scope for ophthalmology encompasses surgical devices, diagnostic tools, corrective lenses, and medication aimed at treating conditions like glaucoma, cataracts, age-related macular degeneration, and diabetic retinopathy. The necessity for innovative ophthalmological solutions is underscored by the aging global population, rising diabetes cases, and increased screen time, contributing to eye strain and vision problems. end-use segments primarily include hospitals, ambulatory surgical centers, and specialized eye clinics. Key growth factors influencing the ophthalmology market include rapid technological innovations such as AI and machine learning in diagnostics, development of minimally invasive surgical techniques, and an upsurge in R&D investments. A promising opportunity lies in tele-ophthalmology, which can enhance access to eye care in remote areas and optimize practice workflows. Gene therapy and personalized medicine also present transformative potential by targeting genetic disorders affecting vision. However, the market faces limitations like high costs associated with advanced treatments and devices, stringent regulatory guidelines, and a shortage of skilled professionals. These challenges necessitate adaptive strategies, such as cost-effective device development and regulatory process navigation. The best areas for innovation and research involve smart contact lenses, AI-powered diagnostic tools, and advancements in retinal scans, which promise improved early detection and treatment of eye conditions. The ophthalmology market's nature is characterized by its competitive landscape, which demands continuous innovation and adaptation to meet emerging trends and patient needs. To leverage these opportunities, businesses should invest in R&D, prioritize partnerships for technological advancement, and focus on patient-centric solutions that enhance care delivery while addressing cost concerns and improving access to eye care services globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Ophthalmology Market

The Ophthalmology Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of eye disorders and growing awareness among the population
  • Increasing adoption of prescription glasses and lenses
  • Presence of well-equipped healthcare infrastructure and an increasing number of drug approvals
• Market Restraints
  • High cost of ophthalmologic treatments
• Market Opportunities
  • Emerging research activities of ophthalmology treatments and availability of grants
  • High usage potential owing to the technological integrations in Ophthalmology
• Market Challenges
  • Limited skilled professionals for ophthalmic procedures

Porter's Five Forces: A Strategic Tool for Navigating the Ophthalmology Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Ophthalmology Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Ophthalmology Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Ophthalmology Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Ophthalmology Market

A detailed market share analysis in the Ophthalmology Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Ophthalmology Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Ophthalmology Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Ophthalmology Market

A strategic analysis of the Ophthalmology Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ophthalmology Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcon Inc., Alkeus Pharmaceuticals, Inc., Apotex Inc., Bausch + Lomb Corporation, C.H. Boehringer Sohn AG & Co. KG, Carl Zeiss AG, ClearSight LLC, CooperVision, Inc., Duopharma Biotech Berhad, Essex Bio-Technology Limited, EssilorLuxottica S.A., Eyenovia, Inc., F. Hoffmann-La Roche AG, GenSight Biologics S.A., Geri-Care Pharmaceuticals Corp., Glaukos Corporation, Halma PLC, Harrow Health, Inc., Honeywell International Inc., Hoya Corporation, Johnson & Johnson Services Inc., Kubota Pharmaceutical Holdings Co., Ltd., Lumenis Be Ltd., Nidek Co., Ltd., Novartis AG, OCuSOFT, Inc., Oxurion NV, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., SEED Co., Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Topcon Corporation, Unimed Pharma, Spols r.o., and Visioncare Optolab Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Ophthalmology Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Diseases, market is studied across Age-Related Macular Degeneration, Cataract, Glaucoma, Inflammatory Diseases, and Refractive Disorders.
• Based on Product Type, market is studied across Drugs, Equipment, Prescription Glasses & Lens, and Software. The Drugs is further studied across Allergic Conjunctivitis & Inflammation Drugs, Dry Eye Drugs, Glaucoma Drugs, and Retinal Disorder Drugs. The Equipment is further studied across Diagnostic Devices and Surgical Devices. The Surgical Devices is further studied across Intraocular Lenses and Ophthalmic Lasers.
• Based on End User, market is studied across Healthcare Service Providers, Hospitals, Medical Institutes, and Research Organizations.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of eye disorders and growing awareness among the population
    • 5.1.1.2. Increasing adoption of prescription glasses and lenses
    • 5.1.1.3. Presence of well-equipped healthcare infrastructure and an increasing number of drug approvals
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of ophthalmologic treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging research activities of ophthalmology treatments and availability of grants
    • 5.1.3.2. High usage potential owing to the technological integrations in Ophthalmology
  • 5.1.4. Challenges
    • 5.1.4.1. Limited skilled professionals for ophthalmic procedures
• 5.2. Market Segmentation Analysis
  • 5.2.1. Diseases: Prevalence of refractive errors such as myopia, hyperopia, astigmatism, and presbyopia in a significant portion of the population
  • 5.2.2. Product Type: Increasing investments in software development in ophthalmology
  • 5.2.3. End User: Continuous research activities by medical institutes worldwide
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Ophthalmology Market, by Diseases

• 6.1. Introduction
• 6.2. Age-Related Macular Degeneration
• 6.3. Cataract
• 6.4. Glaucoma
• 6.5. Inflammatory Diseases
• 6.6. Refractive Disorders

7. Ophthalmology Market, by Product Type

• 7.1. Introduction
• 7.2. Drugs
  • 7.2.1. Allergic Conjunctivitis & Inflammation Drugs
  • 7.2.2. Dry Eye Drugs
  • 7.2.3. Glaucoma Drugs
  • 7.2.4. Retinal Disorder Drugs
• 7.3. Equipment
  • 7.3.1. Diagnostic Devices
  • 7.3.2. Surgical Devices
    • 7.3.2.1. Intraocular Lenses
    • 7.3.2.2. Ophthalmic Lasers
• 7.4. Prescription Glasses & Lens
• 7.5. Software

8. Ophthalmology Market, by End User

• 8.1. Introduction
• 8.2. Healthcare Service Providers
• 8.3. Hospitals
• 8.4. Medical Institutes
• 8.5. Research Organizations

9. Americas Ophthalmology Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Ophthalmology Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Ophthalmology Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Beacon Therapeutics secures USD 170 Million in series B funding to propel ophthalmic gene therapies and drive global expansion
  • 12.3.2. Thea Pharma Inc. introduced new resources to support latanoprost ophthalmic solution patients
  • 12.3.3. BioPhta raises EUR 6.5 million to propel innovative eye disease treatments to clinical trials and expand global reach
  • 12.3.4. Clario and EmSere forge strategic partnership to revolutionize ophthalmic clinical trials with advanced imaging and data integration
  • 12.3.5. Biocon Biologics Limited received U.S. FDA approval for biosimilar aflibercept, enters U.S. ophthalmology market
  • 12.3.6. Topcon and Microsoft join forces to revolutionize ophthalmic diagnostics with AI-powered healthcare platform
  • 12.3.7. A collaboration between Eye2Gene Limited and Heidelberg Engineering, Inc. was announced at ARVO 2024
  • 12.3.8. Nordic Pharma, Inc. gears up for LACRIFILL launch at ASCRS annual meeting
  • 12.3.9. Clario and Cleveland Clinic Foundation's Cole Eye Institute formed a strategic partnership for enhanced ophthalmology clinical trials
  • 12.3.10. Refocus Eye Health is partnering with eight premier practices in New Jersey to enhance specialized eye services
  • 12.3.11. Ikerian AG unveiled a discovery core platform for enhanced ophthalmic data analysis
  • 12.3.12. Cipla joins forces with CSIR-CDRI to innovate ophthalmic antifungal treatments, accelerating R&D and global market reach
• 12.4. Strategy Analysis & Recommendation
  • 12.4.1. Alcon Inc.
  • 12.4.2. EssilorLuxottica S.A.
  • 12.4.3. AbbVie Inc.
  • 12.4.4. Bausch + Lomb Corporation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Alcon Inc.
• 3. Alkeus Pharmaceuticals, Inc.
• 4. Apotex Inc.
• 5. Bausch + Lomb Corporation
• 6. C.H. Boehringer Sohn AG & Co. KG
• 7. Carl Zeiss AG
• 8. ClearSight LLC
• 9. CooperVision, Inc.
• 10. Duopharma Biotech Berhad
• 11. Essex Bio-Technology Limited
• 12. EssilorLuxottica S.A.
• 13. Eyenovia, Inc.
• 14. F. Hoffmann-La Roche AG
• 15. GenSight Biologics S.A.
• 16. Geri-Care Pharmaceuticals Corp.
• 17. Glaukos Corporation
• 18. Halma PLC
• 19. Harrow Health, Inc.
• 20. Honeywell International Inc.
• 21. Hoya Corporation
• 22. Johnson & Johnson Services Inc.
• 23. Kubota Pharmaceutical Holdings Co., Ltd.
• 24. Lumenis Be Ltd.
• 25. Nidek Co., Ltd.
• 26. Novartis AG
• 27. OCuSOFT, Inc.
• 28. Oxurion NV
• 29. Pfizer, Inc.
• 30. Santen Pharmaceutical Co., Ltd.
• 31. SEED Co., Ltd.
• 32. Sun Pharmaceutical Industries Limited
• 33. Teva Pharmaceutical Industries Ltd.
• 34. Topcon Corporation
• 35. Unimed Pharma, Spols r.o.
• 36. Visioncare Optolab Pvt. Ltd.